GSK’s 2025 Report: Climate Action & Healthcare Access

GSK works on treating and preventing diseases in 70 markets worldwide, with more than 66,000 employees and 58 medicines and vaccines in development.

It is working towards its goal of positively impacting the health of 2.5 billion people by the end of the decade.

GSK has released its 2025 Responsible Business Report alongside its Annual Report.

Serving local communities

With people in low-income countries facing increasingly complex and urgent challenges, healthcare companies are responsible for tackling the issues that undermine access to medicines.

As part of its broader commitment to building resilient health systems, GSK has expanded its partnerships around the world helping communities access prevention and care support.

In 2025, GSK and ViiV Healthcare committed £6m (US$8m) – with £6m (US$8m) match-funding from the Gates Foundation – to the Global Fund.

This aims to accelerate community-led responses to high-burden infectious diseases like HIV, TB and malaria.

Sir Jonathan Symonds, Chair of GSK, says: “On almost every measure, GSK is now a changed company – with a confident, ambitious purpose; clear strategic priorities; a stronger pipeline and more balanced portfolio; a sharper focus on capital allocation and a reformed culture where talented people can focus on what matters most and be accountable for delivery.

“At the same time, GSK has kept what makes the company special – a distinctive focus on people and patients, a truly global reach and a deep commitment to do the right thing.”

Improving health access

GSK is making progress towards its 2030 goal of reaching 1.3 billion people in lower income countries with its products.

In 2025, it supplied 560 million doses of its products to lower income countries, putting it on track to achieve this goal.

GSK’s commitment is to make its products available at value-based prices that are sustainable for the business, as well as implementing access strategies to help its medicines treat and protect underserved populations.

According to GSK, access has to start with understanding patients, in terms of how a disease affects them and the context in which they access care.

It focuses on partnering with global health organisations, local governments and communities to reach people affected by disease.

Luke Miels, CEO of GSK, says: “In 2025, we delivered another year of strong performance as a responsible business.

“Looking ahead, we remain committed to maintaining these high standards and to further evolving our approach to create value for shareholders and better outcomes for patients.”

Environmental stewardship

In 2025, GSK achieved a 45% fall in operational carbon emissions from its 2020 baseline.

It also achieved its 2025 target of having 100% imported renewable electricity.

GSK’s long-term goal is to commit to a net zero, nature positive, healthier planet with goals set for 2030 and 2045.

It aims to improve the environmental sustainability of its products and business to help meet customer demand and ensure a resilient supply chain.

This is to help mitigate the impacts of climate change and nature loss, which are changing the spread and burden of disease by posing a threat to human health.

This is increasing the pressure on global healthcare systems, meaning companies like GSK are responding to the growing need for climate action.

Claire Lund, outgoing Vice President Sustainability at GSK, writes on LinkedIn: “We’ve published our 2025 Responsible Business Report setting out the progress we’ve made. This marks the halfway point for many of our climate and nature targets and I’m particularly pleased that we’ve achieved our 2025 short-term targets.

“To share a few of my personal highlights – we’ve made significant progress transitioning to low carbon inhalers, embedded eco-design into all new products and we’re working with our suppliers to access renewable energy.

“We were also the first pharmaceutical company to have Science Based Targets Network (SBTN) validated nature targets and launched a multi-year landscape and restoration partnership with WWF UK.”